Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
25 hedge funds and large institutions have $11.3M invested in Evelo Biosciences, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 15 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less capital invested
Capital invested by funds: $15.5M → $11.3M (-$4.19M)
36% less funds holding
Funds holding: 39 → 25 (-14)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$275K |
| 2 |
Morgan Stanley
New York
|
+$8.25K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.06K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$3.03K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$395 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.03M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$152K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33.3K |
| 4 |
State Street
Boston,
Massachusetts
|
-$27.5K |
| 5 |
TOCUITCONY
Trustees of Columbia University in the City of New York
New York
|
-$20.6K |
EVLO Hedge Fund Activity: Q2 2023 in Review
25 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q2 2023, worth a combined $11.3M — down 27% from $15.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of EVLO and 1 opened new positions — a net loss of 14 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Barclays, adding an estimated $275K. The largest seller was Fidelity Investments, cutting an estimated $2.03M.
- 25 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q2 2023, down from 39 in Q1 2023.
- Funds reported $11.3M of Evelo Biosciences, Inc. Common Stock stock for Q2 2023, down 27% quarter-over-quarter.
- 1 fund opened new Evelo Biosciences, Inc. Common Stock positions in Q2 2023 and 15 closed out, a net change of -14 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q2 2023 was Barclays, an estimated $275K added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q2 2023 was Fidelity Investments, an estimated $2.03M sold.
Based on aggregated 13F filings for Q2 2023.